Given that immune checkpoint inhibitors (ICIs) enhance the anti-cancer activity of CD8+ T cells, oAd5/3-TBD-GFP emerges as a promising combinatory partner for ICIs, providing a targeted approach to cancer therapy. The gene discussed is CD8A; the disease is cancer.